S&P 500   3,803.00 (+1.39%)
DOW   30,749.16 (+1.47%)
QQQ   323.24 (+1.19%)
AAPL   139.47 (-1.82%)
MSFT   238.25 (+2.30%)
FB   274.49 (+0.86%)
GOOGL   1,857.99 (+2.15%)
AMZN   3,263.05 (+0.94%)
TSLA   817.84 (-5.36%)
NVDA   525.39 (+1.68%)
BABA   258.80 (-0.56%)
CGC   39.32 (+3.94%)
GE   11.33 (-0.44%)
MU   77.95 (+3.81%)
AMD   88.89 (+0.06%)
NIO   55.77 (-2.41%)
T   29.62 (+1.65%)
F   10.83 (+0.37%)
ACB   12.07 (+7.77%)
BA   198.02 (+2.06%)
DIS   168.57 (+3.40%)
NFLX   543.83 (+3.93%)
GILD   65.84 (+0.55%)
S&P 500   3,803.00 (+1.39%)
DOW   30,749.16 (+1.47%)
QQQ   323.24 (+1.19%)
AAPL   139.47 (-1.82%)
MSFT   238.25 (+2.30%)
FB   274.49 (+0.86%)
GOOGL   1,857.99 (+2.15%)
AMZN   3,263.05 (+0.94%)
TSLA   817.84 (-5.36%)
NVDA   525.39 (+1.68%)
BABA   258.80 (-0.56%)
CGC   39.32 (+3.94%)
GE   11.33 (-0.44%)
MU   77.95 (+3.81%)
AMD   88.89 (+0.06%)
NIO   55.77 (-2.41%)
T   29.62 (+1.65%)
F   10.83 (+0.37%)
ACB   12.07 (+7.77%)
BA   198.02 (+2.06%)
DIS   168.57 (+3.40%)
NFLX   543.83 (+3.93%)
GILD   65.84 (+0.55%)
S&P 500   3,803.00 (+1.39%)
DOW   30,749.16 (+1.47%)
QQQ   323.24 (+1.19%)
AAPL   139.47 (-1.82%)
MSFT   238.25 (+2.30%)
FB   274.49 (+0.86%)
GOOGL   1,857.99 (+2.15%)
AMZN   3,263.05 (+0.94%)
TSLA   817.84 (-5.36%)
NVDA   525.39 (+1.68%)
BABA   258.80 (-0.56%)
CGC   39.32 (+3.94%)
GE   11.33 (-0.44%)
MU   77.95 (+3.81%)
AMD   88.89 (+0.06%)
NIO   55.77 (-2.41%)
T   29.62 (+1.65%)
F   10.83 (+0.37%)
ACB   12.07 (+7.77%)
BA   198.02 (+2.06%)
DIS   168.57 (+3.40%)
NFLX   543.83 (+3.93%)
GILD   65.84 (+0.55%)
S&P 500   3,803.00 (+1.39%)
DOW   30,749.16 (+1.47%)
QQQ   323.24 (+1.19%)
AAPL   139.47 (-1.82%)
MSFT   238.25 (+2.30%)
FB   274.49 (+0.86%)
GOOGL   1,857.99 (+2.15%)
AMZN   3,263.05 (+0.94%)
TSLA   817.84 (-5.36%)
NVDA   525.39 (+1.68%)
BABA   258.80 (-0.56%)
CGC   39.32 (+3.94%)
GE   11.33 (-0.44%)
MU   77.95 (+3.81%)
AMD   88.89 (+0.06%)
NIO   55.77 (-2.41%)
T   29.62 (+1.65%)
F   10.83 (+0.37%)
ACB   12.07 (+7.77%)
BA   198.02 (+2.06%)
DIS   168.57 (+3.40%)
NFLX   543.83 (+3.93%)
GILD   65.84 (+0.55%)
Log in
NASDAQ:CYCC

Cyclacel Pharmaceuticals Stock Forecast, Price & News

$7.79
+0.40 (+5.41 %)
(As of 01/28/2021 10:15 AM ET)
Add
Compare
Today's Range
$7.51
Now: $7.79
$7.80
50-Day Range
$4.13
MA: $7.02
$9.53
52-Week Range
$3.12
Now: $7.79
$19.25
Volume5,003 shs
Average Volume307,194 shs
Market Capitalization$37.89 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias. Its oncology development programs also comprise sapacitabine, an oral nucleoside analogue prodrug that is in Phase 1/2 combination study with seliciclib, a CDK inhibitor in patients with BRCA mutations; with olaparib, a poly ADP-ribose polymerase inhibitor in BRCA mutation positive patients with breast cancer; and Phase III clinical trial for the treatment of acute myeloid leukemia. In addition, the company's oncology development programs include seliciclib, a CDK inhibitor that is in all-oral Phase 1/2 combination study with sapacitabine for BRCA mutations. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias; and collaboration, licensing, and supply agreement with ManRos Therapeutics SA for the development and commercialization of oral seliciclib capsules for the treatment of cystic fibrosis. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.
Cyclacel Pharmaceuticals logo

MarketRank

Overall MarketRank

0.71 out of 5 stars

Medical Sector

1192nd out of 1,926 stocks

Pharmaceutical Preparations Industry

548th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYCC
CUSIPN/A
Phone908-517-7330
Employees12
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$150,000.00
Book Value$13.60 per share

Profitability

Net Income$-7,830,000.00

Miscellaneous

Market Cap$37.89 million
Next Earnings Date2/24/2021 (Estimated)
OptionableNot Optionable
$7.79
+0.40 (+5.41 %)
(As of 01/28/2021 10:15 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CYCC News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cyclacel Pharmaceuticals (NASDAQ:CYCC) Frequently Asked Questions

How has Cyclacel Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Cyclacel Pharmaceuticals' stock was trading at $0.5399 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CYCC shares have increased by 1,342.9% and is now trading at $7.79.
View which stocks have been most impacted by COVID-19
.

Is Cyclacel Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cyclacel Pharmaceuticals stock.
View analyst ratings for Cyclacel Pharmaceuticals
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cyclacel Pharmaceuticals?

Wall Street analysts have given Cyclacel Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cyclacel Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Spiro Rombotis' approval rating as Cyclacel Pharmaceuticals' CEO?

1 employees have rated Cyclacel Pharmaceuticals CEO Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among Cyclacel Pharmaceuticals' employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Cyclacel Pharmaceuticals' next earnings date?

Cyclacel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 24th 2021.
View our earnings forecast for Cyclacel Pharmaceuticals
.

How were Cyclacel Pharmaceuticals' earnings last quarter?

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) posted its earnings results on Monday, November, 16th. The biotechnology company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.55) by $0.08.
View Cyclacel Pharmaceuticals' earnings history
.

When did Cyclacel Pharmaceuticals' stock split? How did Cyclacel Pharmaceuticals' stock split work?

Cyclacel Pharmaceuticals's stock reverse split on the morning of Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 14th 2020. An investor that had 100 shares of Cyclacel Pharmaceuticals stock prior to the reverse split would have 5 shares after the split.

Are investors shorting Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 211,700 shares, an increase of 221.7% from the December 15th total of 65,800 shares. Based on an average daily volume of 380,900 shares, the short-interest ratio is presently 0.6 days. Currently, 4.0% of the shares of the stock are sold short.
View Cyclacel Pharmaceuticals' Short Interest
.

Who are some of Cyclacel Pharmaceuticals' key competitors?

What other stocks do shareholders of Cyclacel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

Who are Cyclacel Pharmaceuticals' key executives?

Cyclacel Pharmaceuticals' management team includes the following people:
  • Mr. Spiro George Rombotis, Pres, CEO & Exec. Director (Age 62, Pay $728.8k)
  • Mr. Paul McBarron, Exec. VP of Fin., CFO, COO, Sec. & Exec. Director (Age 60, Pay $378.09k)
  • Dr. Judy H. Chiao, VP of Clinical Devel. & Regulatory Affairs (Age 61, Pay $505.06k)
  • Ms. Gill Christie, Director of HR (Age 64)
  • Dr. Robert Westwood Ph.D., Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel. (Age 77)
  • Dr. Mark H. Kirschbaum M.D., Sr. VP & Chief Medical Officer

What is Cyclacel Pharmaceuticals' stock symbol?

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

How do I buy shares of Cyclacel Pharmaceuticals?

Shares of CYCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cyclacel Pharmaceuticals' stock price today?

One share of CYCC stock can currently be purchased for approximately $7.79.

How big of a company is Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals has a market capitalization of $37.89 million and generates $150,000.00 in revenue each year. Cyclacel Pharmaceuticals employs 12 workers across the globe.

What is Cyclacel Pharmaceuticals' official website?

The official website for Cyclacel Pharmaceuticals is www.cyclacel.com.

How can I contact Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The biotechnology company can be reached via phone at 908-517-7330 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.